Tapewire

Nasdaq · USD

PRQR

ProQR Therapeutics N.V.

Export transactions ↓
Tapewire entity
5946
SEC CIK
0001612940
Parsed reports
18

Last 12 months

Inside the activity.

5 purchase rows · 0 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 202600
Feb 202600
Mar 202600
Apr 202600
May 202600
Jun 202610
Jul 202640
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
July 31, 2026 Filed Aug 3, 2026 20:01 UTC
de Boer Daniel AntonDirector · Chief Executive Officer
PurchaseOrdinary Shares 200,000 $1.77 $353,960.00
Disclosure

SEC source: 0001104659-26-089780 · tm2622051-1_4seq1.xml · nonDerivative · entry 1

de Boer Daniel Anton · CIK 0002117546 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Read SEC document
July 17, 2026 Filed Jul 21, 2026 12:00 UTC
Filius BartDirector
PurchaseOrdinary Shares 150,000 $1.72 $257,925.00
Disclosure

SEC source: 0001104659-26-085234 · tm2620903-1_4seq1.xml · nonDerivative · entry 1

Filius Bart · CIK 0002115417 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Read SEC document
July 09, 2026 Filed Jul 13, 2026 12:00 UTC
de Boer Daniel AntonDirector · Chief Executive Officer
PurchaseOrdinary Shares 150,000 $1.74 $261,000.00
Disclosure

SEC source: 0001104659-26-082890 · tm2620241-1_4seq1.xml · nonDerivative · entry 1

de Boer Daniel Anton · CIK 0002117546 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Read SEC document
July 07, 2026 Filed Jul 8, 2026 18:55 UTC
de Boer Daniel AntonDirector · Chief Executive Officer
PurchaseOrdinary Shares 150,000 $1.59 $238,500.00
Disclosure

SEC source: 0001104659-26-081762 · tm2620064-1_4seq1.xml · nonDerivative · entry 1

de Boer Daniel Anton · CIK 0002117546 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Read SEC document
June 26, 2026 Filed Jun 30, 2026 20:01 UTC
Filius BartDirector
PurchaseOrdinary Shares 150,000 $1.54 $231,000.00
Disclosure

SEC source: 0001104659-26-079316 · tm2619428-1_4seq1.xml · nonDerivative · entry 1

Filius Bart · CIK 0002115417 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Read SEC document
June 02, 2026 Filed Jun 3, 2026 20:01 UTC GrantShare Option (Right to Buy) · Derivative 14,495 $0.00 Strike: $1.42 $0.00
Disclosure

SEC source: 0001104659-26-070090 · tm2616802-1_4seq1.xml · derivative · entry 1

Hinsch Gylvin Lykke · CIK 0002135139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,495

Underlying: Ordinary Shares · 14,495 shares

Expires 2036-06-01

F1 · derivative.exercise_price: The price reported in Column 2 is based upon the closing market price of the Issuer's ordinary shares on June 1, 2026, as determined pursuant to the Issuer's Board Compensation Policy.

F2 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on June 2, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document
June 02, 2026 Filed Jun 30, 2026 20:02 UTC Amendment GrantShare Option (Right to Buy) · Derivative 14,595 $0.00 Strike: $1.42 $0.00
Disclosure

SEC source: 0001104659-26-079319 · tm2619428-2_4aseq1.xml · derivative · entry 1

Hinsch Gylvin Lykke · CIK 0002135139 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,595

Underlying: Ordinary Shares · 14,595 shares

Expires 2036-06-01

F1 · derivative.exercise_price: The price reported in Column 2 is based upon the closing market price of the Issuer's ordinary shares on June 1, 2026, as determined pursuant to the Issuer's Board Compensation Policy.

F2 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on June 2, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.